RhumbLine Advisers
ALXO icon

RhumbLine Advisers’s ALX Oncology ALXO Stock Holding History

RhumbLine Advisers’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
+107,902
New +$193K ﹤0.01% 3226
2025
Q2 		– Sell
-46,302
Closed -$28.8K – 4145
2025
Q1 		$28.8K Buy
46,302
+3,786
+9% +$4.54K ﹤0.01% 3679
2024
Q4 		$71K Buy
42,516
+405
+1% +$623 ﹤0.01% 3578
2024
Q3 		$76.6K Sell
42,111
-13,109
-24% -$48.7K ﹤0.01% 3586
2024
Q2 		$333K Buy
55,220
+5,360
+11% +$65.9K ﹤0.01% 2938
2024
Q1 		$556K Buy
49,860
+1,706
+4% +$24K ﹤0.01% 2608
2023
Q4 		$717K Sell
48,154
-2,803
-6% -$26.6K ﹤0.01% 2458
2023
Q3 		$245K Buy
50,957
+607
+1% +$3.29K ﹤0.01% 3044
2023
Q2 		$378K Buy
50,350
+11,443
+29% +$74.9K ﹤0.01% 2869
2023
Q1 		$176K Buy
38,907
+930
+2% +$7.04K ﹤0.01% 2760
2022
Q4 		$428K Buy
37,977
+5,467
+17% +$61.4K ﹤0.01% 2540
2022
Q3 		$311K Buy
32,510
+3,523
+12% +$41.1K ﹤0.01% 2712
2022
Q2 		$235K Buy
28,987
+10,614
+58% +$116K ﹤0.01% 2865
2022
Q1 		$311K Buy
18,373
+1,054
+6% +$18K ﹤0.01% 2632
2021
Q4 		$372K Sell
17,319
-302
-2% -$13K ﹤0.01% 2628
2021
Q3 		$1.3M Buy
17,621
+1,415
+9% +$94.3K ﹤0.01% 2111
2021
Q2 		$886K Sell
16,206
-2,069
-11% -$124K ﹤0.01% 2298
2021
Q1 		$1.35M Buy
18,275
+7,311
+67% +$575K ﹤0.01% 2071
2020
Q4 		$945K Buy
10,964
+2,727
+33% +$164K ﹤0.01% 2157
2020
Q3 		$311K Buy
+8,237
New +$324K ﹤0.01% 2505

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

RhumbLine Advisers's ALXO Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in ALX Oncology (ALXO) in Q2 2026: 107,902 shares worth $223K. The stake represents ﹤0.01% of the portfolio and ranks #3226 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ALXO as recently as Q1 2025.

RhumbLine Advisers first reported a position in ALXO in Q3 2020 and has held it in 20 quarters since. The position peaked at $1.35M in Q1 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • RhumbLine Advisers held 107,902 shares of ALX Oncology worth $223K as of Q2 2026.
  • ALX Oncology was a new RhumbLine Advisers position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3226 holding.
  • RhumbLine Advisers first reported a position in ALX Oncology in Q3 2020 and has held it in 20 quarters since.
  • RhumbLine Advisers's ALX Oncology position peaked at $1.35M in Q1 2021.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.